The Latest Cardiac and Vascular News
January 22, 2025 06:20 AM Eastern Standard Time NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. “2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating […]
BOZEMAN, Mont., Jan. 22, 2025 /PRNewswire/ — Atrial fibrillation (AF) is the most common abnormal heart rhythm affecting 6 million people in the USA and can cause strokes and heart failure. Conventional treatments are successful but may need to be repeated, have inherent risks, and are…
MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February…
MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented […]
January 21, 2025 10:10 AM Eastern Standard Time TEMPE, Ariz.–(BUSINESS WIRE)–Aptyx, a leading global developer and manufacturer of complex components and devices for the life sciences, today announced the acquisition of the Charlotte, North Carolina facility of Medical Murray, which […]
[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received orphan drug status as a diagnostic for the management of AL amyloidosis in EU and US The…
MIAMI, Jan. 21, 2025 /PRNewswire/ — The Amavita Foundation, a leading organization dedicated to advancing cardiovascular health and supporting patients facing chronic limb-threatening ischemia (CLTI), is pleased to announce the appointment of Patty Vila to its Board of Directors. A…
LINCOLN, Neb., Jan. 21, 2025 /PRNewswire/ — Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food security solutions, announced today the launch of Igenity® BCHF to improve overall bovine heart health standards. Bovine Congestive Heart Failure (BCHF) stands as a significant…
– Plans for filing an IND was agreed with the FDA in a recent meeting –
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥60%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy.
